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Abstract Determination of infectious progeny virus and in vivo
labelling with [35S]methionine followed by immunoprecipitation
demonstrates that the major receptor group human rhinovirus
HRV14 is able to infect HeLa cells in the presence of the V-
ATPase inhibitor bafilomycin A1. However, host cell shut off is
delayed and viral yield is decreased in the presence of the drug.
Uncoating can thus take place under conditions that prevent
endosomal acidification indicating that it is catalysed by the viral
receptor alone. Since transport is arrested in early endosomes
upon inhibition of vesicle acidification, the data also suggest that
productive uncoating takes place from early endocytic compart-
ments.
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1. Introduction
Human rhinoviruses (HRVs) are small RNA-viruses consti-
tuting a separate genus within the family picornaviridae. Based
on the receptor used for cell entry, two groups have been
de¢ned [1]. The major group uses intercellular adhesion mol-
ecule-1 (ICAM-1) as a receptor while the minor group gains
access to the host cell via members of the low-density lip-
oprotein receptor (LDLR) family [2^4]. The rhinovirus capsid
can adopt three conformational states. Native virus sediments
at 150S; A-particles are formed upon interaction with the host
cell, have lost the capsid protein VP4, and sediment with 125^
135S. These subviral particles are considered to be either a
transition state in the uncoating pathway or a product of
abortive infection. Finally, B-particles, sedimenting at 80S,
remain after the release of the genomic RNA. The conforma-
tional changes represent a major step in viral entry and are
clearly triggered by the host cell. In vitro, rhinoviruses are
converted to A-particles upon exposure to low pH and to
B-particles by heating to 56‡C [5]. For major receptor group
viruses, structural modi¢cations to 135S or to 80S particles
also occur upon interaction with recombinant soluble ICAM-
1 in a strongly temperature-dependent manner [6,7].
We have shown previously that uncoating of HRV2, a mi-
nor group virus, requires uptake into late endosomes or endo-
somal carrier vesicles for uncoating to occur [8^10]. RNA
release strictly depends on the low endosomal pH with the
receptor being used only as a vehicle for cell entry. In contrast
to HRV2, cellular uptake of HRV14 is slow and less e⁄cient
[11] possibly because ICAM-1 lacks typical coated pit local-
isation signals which are present in recycling receptors such as
LDLR [12,13]. Nevertheless, some degradation of HRV14
starting at 60 min p.i. is clearly indicative of endocytosis
and transport to lysosomes [11]. Moreover, in previous
work we have explicitly demonstrated viral internalisation
into endosomes by free-£ow electrophoretic analysis of homog-
enates prepared from HeLa cells infected with HRV14 [14].
Since all rhinoviruses are acid labile, it has been commonly
thought that uncoating requires uptake into acidic endosomal
compartments [15^18]. However, the ICAM-1-induced con-
formational change in vitro proceeds at neutral pH without
any synergistic e¡ect of mildly acid pH [7]. This suggests that
the ‘catalytic activity’ of the receptor might be su⁄cient for
uncoating in vivo as well. Nevertheless, Perez and Carrasco
reported that inhibition of endosome acidi¢cation resulted in
lack of host cell shut o¡ upon challenge with HRV14 as seen
by continued incorporation of [35S]methionine into cellular
protein. This led them to conclude that HRV14 infection
was dependent on the acidic pH in the endosome lumen
[18]. However, in the course of a study aimed at comparing
the mode of penetration of HRV2 and HRV14 into the cyto-
sol we recently observed that viral protein was being synthe-
sised upon challenge of HeLa cells with HRV14 even under
conditions where endosome acidi¢cation was blocked [14].
In the present study we con¢rm and extend these results by
demonstrating that infectious progeny virus is produced upon
infection of HeLa cells in the presence of ba¢lomycin. How-
ever, the yield of infectious virus was found to be substantially
decreased when compared to control infections. In vivo label-
ling of cellular proteins in the presence of the drug demon-
strated a delay in host cell shut o¡, a reason why viral protein
synthesis might have escaped detection in a previous investi-
gation [18].
2. Materials and methods
2.1. Chemicals
All chemicals and tissue culture media were purchased from Sigma
unless stated otherwise. Ba¢lomycin A1 (a kind gift of Prof. Dr. K.H.
Altendorf) was dissolved in dimethylsulfoxide at 20 mM and stored at
320‡C. The ¢nal concentration of the solvent in the incubation mix-
tures was kept below 1%. [35S]methionine/cysteine (Translabel) was
from American Radiolabeled Chemicals.
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2.2. In vivo labelling of HRV14 and immunoprecipitation
HRV14 and HRV2 (originally obtained from ATCC) were propa-
gated in HeLa cells (Wisconsin strain) and puri¢ed as described [19].
Cells were grown in suspension in S-MEM-Joklik with 7% horse
serum. Virus was labelled as described by Neubauer and colleagues
[15]. For the detection of de novo synthesised viral proteins, cells
(2U105) were preincubated in 1.5 ml plastic tubes by slow rotation
for 30 min in a water bath at 34‡C in 500 Wl of methionine-free MEM
containing 2% foetal calf serum (dialysed against PBS) and 30 mM
MgCl2 (infection medium) in the absence or presence of ba¢lomycin,
at the ¢nal concentrations as stated in the text. Cells were then chal-
lenged with the respective virus (suspended in 100 Wl PBS) at an MOI
of 500. At selected time points, the medium was replaced by fresh
methionine-free infection medium ( þ drug) containing 20 WCi
[35S]methionine and incubation was continued for the times speci¢ed.
Cells were pelleted, boiled in Laemmli sample bu¡er and separated on
SDS-12.5% polyacrylamide minigels. Detection by £uorography was
with Kodak XomatR ¢lms. Alternatively, cells were lysed in 300 Wl
RIPA bu¡er [20] and viral proteins were immunoprecipitated with
rabbit anti-HRV14 antiserum bound to IgG-Sorb (Enzyme Centre)
and analysed as above.
2.3. Determination of infectious progeny virus
HeLa cells grown in 24-well plates were preincubated with or with-
out 400 nM ba¢lomycin in 200 Wl infection medium for 30 min. One
hundred MOI of HRV2 and HRV14, respectively, were added in 200
Wl of the same medium resulting in a ¢nal concentration of ba¢lomy-
cin of 200 nM. After the speci¢ed incubation times, plates were sub-
jected to three freeze/thaw cycles to release cell associated virus, cell
debris was removed by low speed centrifugation and the TCID50 of
the virus in the supernatants was determined accordingly. To those
samples that had not received ba¢lomycin, drug was added prior to
TCID50 determination.
3. Results
3.1. Ba¢lomycin A1 fails to inhibit infection with HRV14
HeLa cells were preincubated in the absence or in the pres-
ence of ba¢lomycin at the ¢nal concentrations as shown in
Fig. 1 and infected with HRV14 at an MOI of 500. At 4.5 h
p.i. [35S]methionine was added to label de novo synthesised
viral proteins. At 19.5 h p.i. progeny virus was recovered from
cell lysates by immunoprecipitation and viral capsid proteins
were detected upon separation on an SDS-polyacrylamide gel
followed by £uorography (for experimental set-up see top of
Fig. 1). When compared to the control experiment (carried
out in the absence of ba¢lomycin, Fig. 1A, lane 1) it becomes
apparent that the continuous presence of the drug at ¢nal
concentrations ranging from 200 nM to 2 WM failed to pre-
vent viral infection as viral capsid proteins appeared almost
equally labelled regardless of the presence of ba¢lomycin. As
we have recently shown that ba¢lomycin at s 200 nM e⁄-
ciently raises the endocytic vesicle pH to neutrality in HeLa
cells [10] this suggests that viral uncoating must have occurred
at neutral pH. In order to investigate whether virus mediated
host cell shut o¡ (i.e. a decline in translation of capped cel-
lular messenger RNAs due to cleavage of the initiation factor
eIF-4G by the viral proteinase 2A [21]) was a¡ected by the
drug, total cell lysates were also analysed without immuno-
precipitation (Fig. 1B). As expected, in the absence of ba¢lo-
mycin (lane 2), viral challenge led to a substantial decrease of
cellular protein synthesis when compared to mock infected
cells (lane 1). However, no host cell shut o¡ had occurred
in the presence of 2 WM ba¢lomycin (compare lanes 2 and
3) at 4.5 h p.i. Moreover, in accordance with earlier results [9],
protein synthesis per se is not a¡ected by ba¢lomycin (com-
pare lanes 1 and 3). This suggests that viral replication was
delayed in the presence of the drug resulting in a lag of virally
induced shut o¡ of host cell protein synthesis. When viral
progeny released from the infected cells and recovered from
the cell supernatant by immunoprecipitation, the amount of
viral proteins synthesised in presence of ba¢lomycin appeared
una¡ected as compared to infection in the absence of the drug
(Fig. 1C). These data clearly establish that HRV14 infection
can occur independently of low endosomal pH and that re-
lease of virus from the cells does not appear to be a¡ected by
the drug.
The lack of host cell shut o¡ at 4.5 h p.i. in the presence of
2 WM ba¢lomycin is in accordance with results of Perez and
Carrasco [18]. However, these workers interpreted their data
as inhibition of infection due to elevation of endosomal pH.
The immunoprecipitation as used in our experiments clearly
demonstrates de novo synthesis of HRV14 in the presence of
the drug, excluding the requirement for low intravesicular pH
during infection.
Fig. 1. E¡ect of ba¢lomycin on viral infection. HeLa cells were pre-
incubated in the presence or absence of ba¢lomycin, infected with
HRV14 and [35S]methionine was added (for experimental set-up see
top). (A) The cell pellet was solubilised, viral proteins were immu-
noprecipitated and separated by SDS-PAGE followed by £uorogra-
phy. For comparison, (B) total protein in the cell pellet or (C) pro-
teins immunoprecipitated from the cell supernatant were also
analysed.
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In order to investigate whether host cell shut o¡ did not
occur under our experimental conditions due to a delay in the
onset of viral protein synthesis, total proteins made in virus
infected cells were monitored by pulse labelling for 1 h at the
times indicated in Fig. 2. The data of this experiment demon-
strate that the peak of viral synthesis indeed occurs with a
delay of about 2 h in the presence of 2 WM ba¢lomycin. As a
consequence, host cell shut o¡ is also delayed explaining the
apparent discrepancy between our data shown in Fig. 1A and
the results of Perez and Carrasco [18].
3.2. Infectious HRV14 is synthesised in the presence of
ba¢lomycin
Incorporation of radioactivity into viral protein does not
necessarily result in production of infectious virions. There-
fore, the in£uence of ba¢lomycin on the synthesis of infectious
virus was assayed by means of TCID50 determination. For
control purposes, the minor group rhinovirus HRV2 was
also included in the analysis as we have previously demon-
strated that ba¢lomycin completely blocked incorporation of
[35S]methionine into capsid proteins of this serotype [9].
HeLa cells grown in 24-well plates were preincubated with
or without 400 nM ba¢lomycin for 30 min. Cells were then
challenged with 1.6U108 TCID50 HRV2 and HRV14, respec-
tively, corresponding to an MOI of 100 (Fig. 3). Where in-
dicated, ba¢lomycin was then maintained at a ¢nal concen-
tration of 200 nM during the whole experiment. One h p.i. the
supernatants containing virus that had not entered the cells
were removed, cells were washed and incubation was contin-
ued in fresh infection medium ( þ 200 nM ba¢lomycin). Plates
were subjected to three freeze/thaw cycles at the times p.i. as
shown in Fig. 3. Samples without drug were adjusted to 200
nM ba¢lomycin prior to TCID50 determination. In the ab-
sence of the drug, HRV2 infection led to a substantial increase
of infectious virus at 20.5 h p.i. when compared to that
present at 1 h p.i. or at 4 h p.i. The latter time point was
chosen to determine the fraction of input virus that had not
undergone uncoating and was thus still present as infectious
particles. However, the increase in viral titre from 1 to 4 h p.i.
indicates some de novo synthesis of progeny virus already at
this early time point. In the presence of ba¢lomycin, the titre
of HRV2 was about one log higher at 1 h p.i. when compared
to the value in the absence of ba¢lomycin. Furthermore, this
value did not change up to 20.5 h p.i. This is taken to indicate
that all virus having entered the cells during the challenge
period (1 h) remained in a native state and had not undergone
uncoating or degradation in lysosomes. As ba¢lomycin does
not a¡ect virus uptake [9] one can assume that the same
number of infectious particles had entered the cells regardless
of the presence of the drug. Therefore, about 90% of inter-
nalised HRV2 must have been uncoated in the absence of the
drug. In accordance with earlier results [9,15] these data thus
clearly con¢rmed that HRV2 synthesis was completely
blocked in the presence of the drug.
For HRV14, in absence of ba¢lomycin, the time-dependent
increase of viral titre was very similar to that of HRV2. Input
virus recovered at 1 h p.i. was also substantially higher in
presence of the drug when compared to the value seen in its
absence. However, at 4 h p.i. viral titre dropped by a factor of
1000 indicating that uncoating had taken place. Finally, the
increase of viral titre at 20.5 h p.i. proves that viral replication
occurs in the presence of ba¢lomycin.
Taken together, our results imply that the receptor alone is
Fig. 2. Delay of virus-induced host cell shut o¡ in the presence of
ba¢lomycin. Cells were preincubated in the absence and presence of
ba¢lomycin, infected, and de novo synthesised proteins were labelled
for 1 h with [35S]methionine at the time points p.i. as indicated.
Analysis of total cellular protein was by SDS-PAGE followed by
autoradiography. For experimental set-up see top of the ¢gure.
Where indicated, ba¢lomycin was present at 2 WM.
Fig. 3. Infectious HRV14 is produced in the presence of ba¢lomy-
cin. HeLa cells grown in 24-well plates were preincubated with ba¢-
lomycin for 30 min at 34‡C and infected with HRV2 or with
HRV14 at an MOI of 100. Where indicated, the drug was then
present throughout the experiment at a ¢nal concentration of 200
nM. At the times speci¢ed, viral titre was determined as TCID50.
Data represent the mean þ S.D. from three independent experiments.
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capable of inducing the structural modi¢cation of the viral
capsid required to initiate RNA release and productive infec-
tion even in the absence of a transmembrane proton gradient.
Nevertheless, whereas HRV2 replication is clearly prevented
by the presence of ba¢lomycin, uncoating of HRV14 proceeds
but synthesis of infectious HRV14 is substantially diminished.
4. Discussion
Using immunoprecipitation of viral proteins we demon-
strated that HRV14 infection of HeLa cells also occurs
when endosome acidi¢cation is prevented by ba¢lomycin
A1, a speci¢c inhibitor of vacuolar H-ATPases. This is in
sharp contrast to HRV2 infection, which is completely
blocked by the same drug (this paper and [8,9]). HRV14 un-
coating thus appears to be catalysed by its receptor alone
under these conditions. Since host cell shut o¡ is retarded in
the presence of the drug (Fig. 2), incorporation of radioactive
methionine into viral proteins might have been missed in pre-
vious work [18].
When the synthesis of radioactively labelled viral proteins
(Fig. 1) was compared to the synthesis of infectious virions
(Fig. 3) in the presence of the drug it became apparent that
the increase in viral titre of HRV14 was much less than that
expected from the radioactivity incorporated. The reason for
this discrepancy is not clear at the present time. The higher
MOI used in the in vivo labelling experiment (500 and 100,
respectively) might override to some extent the delay in host
cell shut o¡. Control experiments (not shown) demonstrated
that addition of ba¢lomycin after viral challenge (1 h p.i.)
neither signi¢cantly inhibited incorporation of radioactivity
into virions nor diminished the viral yield. Therefore, an in-
£uence of ba¢lomycin on assembly of infectious viral particles
is rather unlikely. It should also be mentioned that the extent
of label incorporated into progeny virions was found to sub-
stantially vary from experiment to experiment. We believe
that this is due to the status of the cells which might in£uence
the time of maximal viral synthesis and thus incorporation of
radioactivity. To which extent HRV14 can be uncoated by
ICAM-1 alone might also depend on the presence or absence
(and the nature) of the pocket factor, presumably a fatty acid
which is taken up at some stage during viral assembly and
associates with a hydrophobic pocket in the viral capsid. The
pocket factor is thought to be displaced upon receptor binding
[22,23]. It is conceivable that the nature of this factor is sub-
ject to variations in£uencing the ease of uncoating. Quanti¢-
cation of the e¡ects of ba¢lomycin on the yield of progeny
HRV14 appears di⁄cult ; nevertheless, these data (and data
presented earlier [8,9,14]) unequivocally demonstrate a clear
di¡erence between a minor group rhinovirus (HRV2) and a
major group rhinovirus (HRV14) with respect to their sensi-
tivity towards ba¢lomycin. Whereas uncoating of HRV2 does
not take place upon elevation of the endosomal pH to neu-
trality, HRV14 can uncoat under these conditions although
with variable e⁄ciency.
Ba¢lomycin not only inhibits vesicle acidi¢cation but also
budding of endosomal carrier vesicles from early endosomes
[24]. As we have shown previously, HRV2 and £uid-phase
marker en route to lysosomes are trapped in early compart-
ments under these conditions [10]. Furthermore, we have also
demonstrated that HRV14 gains access to the cytoplasm via
endosome rupture [14] and that this process is not prevented
by the drug. Thus it has to be assumed that uncoating of
HRV14 can occur from early endosomes, does not require
transfer of the virions to endosomal carrier vesicles or late
endosomes and can be mediated by the receptor alone in
the absence of endosome acidi¢cation.
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